Axa’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$344K Buy
675
+322
+91% +$219K 0.37% 40
2026
Q1
$273K Buy
+353
New +$270K 0.11% 66
2025
Q3
Sell
-62,430
Closed -$32.8M 828
2025
Q2
$32.8M Sell
62,430
-20,836
-25% -$11.6M 0.09% 191
2025
Q1
$52.8M Buy
83,266
+2,902
+4% +$2M 0.17% 117
2024
Q4
$57.2M Sell
80,364
-6,413
-7% -$5.38M 0.17% 115
2024
Q3
$91.2M Sell
86,777
-5,877
-6% -$6.54M 0.27% 82
2024
Q2
$97.4M Sell
92,654
-8,499
-8% -$8.24M 0.29% 66
2024
Q1
$97.4M Sell
101,153
-9,324
-8% -$8.87M 0.29% 73
2023
Q4
$97M Sell
110,477
-3,564
-3% -$2.93M 0.31% 72
2023
Q3
$93.9M Buy
114,041
+685
+0.6% +$538K 0.33% 71
2023
Q2
$81.5M Sell
113,356
-28,381
-20% -$21.9M 0.27% 95
2023
Q1
$116M Sell
141,737
-26,010
-16% -$19.6M 0.4% 54
2022
Q4
$121M Buy
167,747
+41,500
+33% +$30.6M 0.44% 46
2022
Q3
$87M Sell
126,247
-4,818
-4% -$3.03M 0.34% 67
2022
Q2
$77.5M Sell
131,065
-3,576
-3% -$2.32M 0.29% 84
2022
Q1
$94M Sell
134,641
-36,434
-21% -$23.1M 0.27% 90
2021
Q4
$108M Sell
171,075
-26,003
-13% -$16M 0.28% 88
2021
Q3
$119M Buy
197,078
+74,696
+61% +$46.4M 0.33% 68
2021
Q2
$68.4M Sell
122,382
-15,653
-11% -$7.93M 0.19% 123
2021
Q1
$65.3M Buy
138,035
+14,590
+12% +$7.1M 0.2% 122
2020
Q4
$59.6M Sell
123,445
-1,993
-2% -$1.08M 0.19% 130
2020
Q3
$70.2M Buy
125,438
+7,896
+7% +$4.79M 0.25% 90
2020
Q2
$73.3M Buy
117,542
+34,201
+41% +$19.4M 0.29% 86
2020
Q1
$40.7M Sell
83,341
-10,438
-11% -$4.31M 0.2% 119
2019
Q4
$35.2M Buy
93,779
+45,751
+95% +$15.4M 0.14% 180
2019
Q3
$13.3M Sell
48,028
-1,850
-4% -$547K 0.05% 391
2019
Q2
$15.6M Sell
49,878
-22,279
-31% -$7.42M 0.06% 355
2019
Q1
$29.6M Buy
72,157
+1,375
+2% +$566K 0.12% 226
2018
Q4
$26.4M Sell
70,782
-22,201
-24% -$8.13M 0.12% 220
2018
Q3
$37.6M Hold
92,983
0.14% 196
2018
Q2
$32.1M Buy
92,983
+1,101
+1% +$344K 0.12% 214
2018
Q1
$31.6M Sell
91,882
-1,296
-1% -$451K 0.13% 198
2017
Q4
$35M Sell
93,178
-283
-0.3% -$115K 0.14% 204
2017
Q3
$41.8M Sell
93,461
-18,450
-16% -$8.78M 0.18% 168
2017
Q2
$55M Buy
111,911
+30,769
+38% +$13.5M 0.25% 113
2017
Q1
$31.4M Sell
81,142
-5,057
-6% -$1.87M 0.14% 200
2016
Q4
$31.6M Sell
86,199
-16,265
-16% -$6.19M 0.15% 185
2016
Q3
$41.2M Buy
102,464
+50
+0% +$20.1K 0.18% 159
2016
Q2
$35.8M Sell
102,414
-3,609
-3% -$1.39M 0.16% 176
2016
Q1
$38.2M Buy
106,023
+677
+0.6% +$279K 0.17% 164
2015
Q4
$57.2M Sell
105,346
-1,303
-1% -$706K 0.25% 112
2015
Q3
$49.6M Sell
106,649
-1,955
-2% -$1.05M 0.2% 136
2015
Q2
$55.4M Sell
108,604
-900
-0.8% -$439K 0.22% 129
2015
Q1
$49.4M Sell
109,504
-4,333
-4% -$1.84M 0.2% 143
2014
Q4
$46.7M Sell
113,837
-7,079
-6% -$2.78M 0.19% 151
2014
Q3
$43.6M Buy
120,916
+75,523
+166% +$25.3M 0.19% 156
2014
Q2
$12.8M Sell
45,393
-1,806
-4% -$535K 0.05% 353
2014
Q1
$14.2M Sell
47,199
-14,510
-24% -$4.47M 0.06% 311
2013
Q4
$17M Sell
61,709
-26,137
-30% -$7.52M 0.08% 275
2013
Q3
$27.5M Sell
87,846
-6,647
-7% -$1.75M 0.14% 182
2013
Q2
$21.3M Buy
+94,493
New +$22M 0.11% 203

Other funds holding REGN

Axa's REGN Position: Q2 2026 in Review

Axa increased its Regeneron Pharmaceuticals (REGN) stake by 91% in Q2 2026, buying an estimated $219K and bringing the position to 675 shares worth $344K. The position accounts for 0.37% of the portfolio, ranked #40.

Axa first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $121M in Q4 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Axa held 675 shares of Regeneron Pharmaceuticals worth $344K as of Q2 2026.
  • Axa bought 322 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $219K.
  • Regeneron Pharmaceuticals made up 0.37% of Axa's portfolio in Q2 2026, its #40 holding.
  • Axa first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Axa's Regeneron Pharmaceuticals position peaked at $121M in Q4 2022.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Axa's 13F filing for Q2 2026, filed 14 Aug 2026.